CinderBio

Executive Summary

CinderBio specializes in producing hyper-stable archaeal enzymes that withstand extreme heat and acidity, making them uniquely suited for demanding industrial and research applications. Their flagship product, HTA-Proteases, enables five-minute, one-step sample digestion for proteomics, significantly accelerating workflows. The company also addresses de novo monoclonal antibody sequencing, alternative protein production, ethanol processing, biofilm removal, and enzymatic cleaning. Founded in 2013 and based in San Francisco, CinderBio operates as a private entity with no disclosed funding rounds, suggesting a lean, technology-driven approach. While the company's enzyme portfolio has broad commercial potential across biopharma, biofuels, and industrial cleaning, the lack of public revenue data and limited online presence temper near-term visibility. Nonetheless, CinderBio's core technology—derived from extremophilic archaea—positions it as a niche but impactful player in the enzyme market, particularly as proteomics and sustainable industrial processes demand faster, more robust reagents.

Upcoming Catalysts (preview)

• Q2 2026Commercial Launch of HTA-Proteases for High-Throughput Proteomics70% success
• Q3 2026Strategic Partnership with Biopharma for mAb Sequencing50% success
• Q4 2026DOE Grant for Enzyme Applications in Biofuels60% success